Autopsy report · NCT05557942
Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL)
Cause of deathOther
“Results from the parent study (IMPAHCT) demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.”
Life of this trial
- Registered 2 months before it started.
- Ran for about 1 year 9 months before it stopped.
- 186 participants enrolled.
- Results were posted on the registry 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Aerovate Therapeutics
- Sponsor type
- Industry
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- AV-101
- Participants
- 186
- Sites
- 72
- Countries
- Argentina, Australia, Belgium, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Latvia and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.